Rallybio (RLYB) Competitors $1.01 -0.02 (-1.94%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RLYB vs. MGTA, CTMX, FBRX, SGMT, LFCR, BDTX, CADL, ACTU, ADVM, and SCLXShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Magenta Therapeutics (MGTA), CytomX Therapeutics (CTMX), Forte Biosciences (FBRX), Sagimet Biosciences (SGMT), Lifecore Biomedical (LFCR), Black Diamond Therapeutics (BDTX), Candel Therapeutics (CADL), Actuate Therapeutics (ACTU), Adverum Biotechnologies (ADVM), and Scilex (SCLX). These companies are all part of the "medical" sector. Rallybio vs. Magenta Therapeutics CytomX Therapeutics Forte Biosciences Sagimet Biosciences Lifecore Biomedical Black Diamond Therapeutics Candel Therapeutics Actuate Therapeutics Adverum Biotechnologies Scilex Rallybio (NASDAQ:RLYB) and Magenta Therapeutics (NASDAQ:MGTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk. Do institutionals & insiders hold more shares of RLYB or MGTA? 90.3% of Rallybio shares are owned by institutional investors. Comparatively, 47.5% of Magenta Therapeutics shares are owned by institutional investors. 7.4% of Rallybio shares are owned by insiders. Comparatively, 15.2% of Magenta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has preferable earnings & valuation, RLYB or MGTA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRallybioN/AN/A-$74.56M-$1.79-0.56Magenta TherapeuticsN/AN/A-$76.46MN/AN/A Does the MarketBeat Community prefer RLYB or MGTA? Magenta Therapeutics received 119 more outperform votes than Rallybio when rated by MarketBeat users. However, 76.00% of users gave Rallybio an outperform vote while only 57.09% of users gave Magenta Therapeutics an outperform vote. CompanyUnderperformOutperformRallybioOutperform Votes3876.00% Underperform Votes1224.00% Magenta TherapeuticsOutperform Votes15757.09% Underperform Votes11842.91% Does the media favor RLYB or MGTA? In the previous week, Rallybio had 2 more articles in the media than Magenta Therapeutics. MarketBeat recorded 2 mentions for Rallybio and 0 mentions for Magenta Therapeutics. Magenta Therapeutics' average media sentiment score of 0.95 beat Rallybio's score of 0.17 indicating that Magenta Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Rallybio Neutral Magenta Therapeutics Positive Which has more risk and volatility, RLYB or MGTA? Rallybio has a beta of -1.7, suggesting that its share price is 270% less volatile than the S&P 500. Comparatively, Magenta Therapeutics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Do analysts recommend RLYB or MGTA? Rallybio currently has a consensus target price of $10.00, suggesting a potential upside of 890.10%. Given Rallybio's higher probable upside, equities research analysts clearly believe Rallybio is more favorable than Magenta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Magenta Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Is RLYB or MGTA more profitable? Magenta Therapeutics' return on equity of -70.88% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets RallybioN/A -74.08% -67.07% Magenta Therapeutics N/A -70.88%-57.27% SummaryRallybio and Magenta Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Ad Timothy SykesAlgo Trading Is Here 🔥One trade alert each day backed by powerful technology, yours free. For $0 you can get access to one daily stock picked directly from StocksToTrade’s algo-powered system.>> Click here to sign up & get the next 🔥alert sent directly to your phone << Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$41.91M$7.42B$5.54B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.569.93114.8115.14Price / SalesN/A396.631,495.55100.10Price / CashN/A47.3939.6734.08Price / Book0.365.324.665.02Net Income-$74.56M$153.56M$119.06M$225.46M7 Day Performance-1.94%0.13%0.80%0.37%1 Month Performance-7.34%15.23%5.65%3.57%1 Year Performance-75.43%41.14%36.75%29.43% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio3.1454 of 5 stars$1.01-1.9%$10.00+890.1%-76.1%$41.91MN/A-0.5640Analyst ForecastMGTAMagenta TherapeuticsN/A$0.70-7.7%N/A+0.0%$42.44MN/A0.0067Gap DownCTMXCytomX Therapeutics4.3032 of 5 stars$1.03-4.6%$5.77+460.4%-2.8%$80.26M$119.57M7.36170Upcoming EarningsNews CoverageFBRXForte Biosciences1.6113 of 5 stars$4.68+1.1%$3.25-30.5%+23,544.3%$170.49MN/A-0.265Options VolumeNews CoverageGap UpHigh Trading VolumeSGMTSagimet Biosciences2.4691 of 5 stars$5.59+1.6%$24.00+329.3%+50.1%$169.90M$2M0.008Analyst ForecastNews CoverageLFCRLifecore Biomedical3.0405 of 5 stars$5.50+2.0%$8.00+45.6%-16.4%$169.80M$128.26M68.69690Positive NewsBDTXBlack Diamond Therapeutics2.2329 of 5 stars$2.98-2.0%$15.50+420.1%+56.6%$167.63MN/A-1.9990Upcoming EarningsShort Interest ↑CADLCandel Therapeutics1.5752 of 5 stars$5.60+1.4%$11.00+96.4%+486.7%$166.63M$120,000.00-3.3160Negative NewsACTUActuate TherapeuticsN/A$8.52+0.4%N/AN/A$166.40MN/A56.8010News CoverageGap UpADVMAdverum Biotechnologies3.8368 of 5 stars$7.98-1.2%$28.17+253.0%-18.8%$165.64M$3.60M-1.00190Short Interest ↑SCLXScilex2.8666 of 5 stars$0.86-3.4%$11.33+1,215.7%-46.3%$165.21M$46.74M-0.6080Gap Up Related Companies and Tools Related Companies Magenta Therapeutics Alternatives CytomX Therapeutics Alternatives Forte Biosciences Alternatives Sagimet Biosciences Alternatives Lifecore Biomedical Alternatives Black Diamond Therapeutics Alternatives Candel Therapeutics Alternatives Actuate Therapeutics Alternatives Adverum Biotechnologies Alternatives Scilex Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RLYB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
